UY35441A - Agentes quelantes de precursores de producto final de glicación avanzada (age). - Google Patents

Agentes quelantes de precursores de producto final de glicación avanzada (age).

Info

Publication number
UY35441A
UY35441A UY0001035441A UY35441A UY35441A UY 35441 A UY35441 A UY 35441A UY 0001035441 A UY0001035441 A UY 0001035441A UY 35441 A UY35441 A UY 35441A UY 35441 A UY35441 A UY 35441A
Authority
UY
Uruguay
Prior art keywords
age
precursors
glication
advanced
final product
Prior art date
Application number
UY0001035441A
Other languages
English (en)
Inventor
Besev Magnus
Robert J Miller
S Randall Holmes-Farley
Dhal Pradeep
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of UY35441A publication Critical patent/UY35441A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F126/00—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
    • C08F126/02—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Polymers & Plastics (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Steroid Compounds (AREA)

Abstract

Los agentes quelantes de precursores de AGE comprenden aminas separadas por 2, 3 o 4 carbonos. Los agentes quelantes de precursores de AGE se pueden usar como agentes farmacéuticos y en composiciones farmacéuticas. Los agentes quelantes de precursores de AGE son precursores de AGE de unión particularmente útiles y dicarbonilos dietéticos en mamíferos en el tracto gastrointestinal para el tratamiento de enfermedades tales como nefropatía diabética, enfermedad renal crónica, aterosclerosis, apoplejía, cataratas, y enfermedad de Alzheimer.
UY0001035441A 2013-03-15 2014-03-14 Agentes quelantes de precursores de producto final de glicación avanzada (age). UY35441A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361792719P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
UY35441A true UY35441A (es) 2014-10-31

Family

ID=50439508

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035441A UY35441A (es) 2013-03-15 2014-03-14 Agentes quelantes de precursores de producto final de glicación avanzada (age).

Country Status (24)

Country Link
US (2) US20160024233A1 (es)
EP (1) EP2968403A1 (es)
JP (4) JP2016512830A (es)
KR (1) KR20150130492A (es)
CN (1) CN105188718A (es)
AR (1) AR095593A1 (es)
AU (2) AU2014235500A1 (es)
BR (1) BR112015023404A8 (es)
CA (1) CA2906501A1 (es)
CL (1) CL2015002624A1 (es)
CR (1) CR20150545A (es)
DO (1) DOP2015000221A (es)
EA (1) EA201591733A1 (es)
HK (1) HK1220607A1 (es)
IL (1) IL241406A0 (es)
MA (1) MA38487A1 (es)
MX (1) MX2015012843A (es)
PE (1) PE20151766A1 (es)
PH (1) PH12015502019A1 (es)
SG (2) SG10201707590XA (es)
TN (1) TN2015000390A1 (es)
TW (1) TW201521744A (es)
UY (1) UY35441A (es)
WO (1) WO2014150873A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41202A (fr) * 2014-12-18 2017-10-24 Genzyme Corp Copolymères polydiallymine réticulé pour le traitement du diabète de type 2
CA3072349A1 (en) * 2017-08-31 2019-03-07 Cytosorbents Corporation Reduction of advanced glycation endproducts from bodily fluids

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985938A (en) * 1997-11-05 1999-11-16 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
DK1923064T3 (en) * 2001-04-18 2017-10-02 Genzyme Corp Use of amine polymer for lowering serum glucose
AU2003263010A1 (en) * 2003-09-02 2005-04-21 Genzyme Corporation Method for reducing vascular inflammation
US7459502B2 (en) * 2003-11-03 2008-12-02 Ilypsa, Inc. Pharmaceutical compositions comprising crosslinked polyamine polymers
US7385012B2 (en) * 2003-11-03 2008-06-10 Ilypsa, Inc. Polyamine polymers
JP2007523908A (ja) * 2004-02-17 2007-08-23 ダイナミス セラピューティクス インコーポレイテッド フルクトサミン３キナーゼ並びにコラーゲン及びエラスチンの形成
FR2883873B1 (fr) * 2005-03-31 2009-07-10 Pharmamens Sarl Inhibiteurs d'age
EP2539380B1 (en) * 2010-02-24 2015-08-19 Relypsa, Inc. Crosslinked polyvinylamine, polyallylamine, and polyethyleneimine for use as bile acid sequestrants

Also Published As

Publication number Publication date
BR112015023404A2 (pt) 2017-07-18
DOP2015000221A (es) 2015-12-15
BR112015023404A8 (pt) 2019-12-03
KR20150130492A (ko) 2015-11-23
SG11201506413PA (en) 2015-09-29
JP2020055850A (ja) 2020-04-09
CA2906501A1 (en) 2014-09-25
EP2968403A1 (en) 2016-01-20
TW201521744A (zh) 2015-06-16
JP2022037143A (ja) 2022-03-08
JP2016512830A (ja) 2016-05-09
HK1220607A1 (zh) 2017-05-12
US20180265613A1 (en) 2018-09-20
SG10201707590XA (en) 2017-11-29
AU2019201259A1 (en) 2019-03-14
US20160024233A1 (en) 2016-01-28
CR20150545A (es) 2015-12-01
PE20151766A1 (es) 2015-12-11
EA201591733A1 (ru) 2016-01-29
JP2018135365A (ja) 2018-08-30
CL2015002624A1 (es) 2016-03-11
CN105188718A (zh) 2015-12-23
WO2014150873A1 (en) 2014-09-25
MA38487A1 (fr) 2017-12-29
TN2015000390A1 (en) 2017-01-03
AU2014235500A1 (en) 2015-11-05
AR095593A1 (es) 2015-10-28
IL241406A0 (en) 2015-11-30
MX2015012843A (es) 2016-08-08
PH12015502019A1 (en) 2016-01-11

Similar Documents

Publication Publication Date Title
CL2021000008A1 (es) Uso de un heparinoide para el tratamiento del cáncer (divisional de la solicitud n° 201403017)
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
EA201890204A1 (ru) Антибактериальные соединения
MX2016013689A (es) Compuestos 4-amino-imidazoquinolina.
TW201613901A (en) New compounds
UY34201A (es) Compuestos de azaindol y métodos para el tratamiento de vih.
TN2015000278A1 (en) Autotaxin inhibitors
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
UY33627A (es) Compuestos para tratar enfermedades neurodegenerativas
EA201400178A1 (ru) Лечение рака молочной железы
CR20130377A (es) Métodos y productos de fármaco para tratar enfermedad de alzheimer
UY34545A (es) Novedosas dihidropirimidinoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios.
UY34859A (es) Análogos peptídicos de la exendina 4.
MX2014014946A (es) Uso de peptidos glp-1 de accion prolongada.
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
UY34615A (es) Nuevos compuestos útiles para el tratamiento de enfermedades degenerativas e inflamatorias.
MX356755B (es) Compuestos de tipo fumagilol y metodos para su elaboración y uso.
CL2015000926A1 (es) Proceso para la elaboración de compuestos para el tratamiento del cancer derivados de azetidin-1-il-metanona y compuestos intermediarios.
PH12017500747B1 (en) Heterocyclic compound
PE20151746A1 (es) Compuestos biciclicos
GEP201606566B (en) Isoxazolidine derivatives
UY35441A (es) Agentes quelantes de precursores de producto final de glicación avanzada (age).
MX2016006544A (es) Witanolidos utiles para el tratamiento de enfermedades neurodegenerativas.
PH12017501695A1 (en) Treatment of type 2 diabetes mellitus patients

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20211112